Y-mAbs to Present at the Oppenheimer 35ᵗʰ Annual Life Sciences Conference
Y-mAbs Therapeutics (Nasdaq: YMAB), a commercial-stage biopharmaceutical company specializing in radioimmunotherapy and antibody-based therapeutic products for cancer treatment, has announced its participation in the Oppenheimer 35th Annual Life Sciences Conference.
The company's President and CEO, Michael Rossi, will engage in a fireside chat scheduled for Tuesday, February 11, 2025, at 4:40 p.m. ET. Investors and interested parties can access a live webcast of the presentation through the Events section on Y-mAbs' investor relations website at ir.ymabs.com. The presentation recording will remain available for replay on the website for 30 days following the event.
Y-mAbs Therapeutics (Nasdaq: YMAB), un'azienda biofarmaceutica in fase commerciale specializzata in radioimmunoterapia e prodotti terapeutici a base di anticorpi per il trattamento del cancro, ha annunciato la sua partecipazione alla 35ª Conferenza Annuale sulle Scienze della Vita di Oppenheimer.
Il Presidente e CEO dell'azienda, Michael Rossi, parteciperà a una chiacchierata informale programmata per martedì 11 febbraio 2025, alle 16:40 ET. Gli investitori e le parti interessate possono accedere a una diretta della presentazione tramite la sezione Eventi sul sito web delle relazioni con gli investitori di Y-mAbs all'indirizzo ir.ymabs.com. La registrazione della presentazione resterà disponibile per il replay sul sito per 30 giorni dopo l'evento.
Y-mAbs Therapeutics (Nasdaq: YMAB), una empresa biofarmacéutica en etapa comercial especializada en radioinmunoterapia y productos terapéuticos basados en anticuerpos para el tratamiento del cáncer, ha anunciado su participación en la 35ª Conferencia Anual de Ciencias de la Vida de Oppenheimer.
El Presidente y CEO de la empresa, Michael Rossi, participará en una charla informal programada para martes 11 de febrero de 2025, a las 4:40 p.m. ET. Los inversores y partes interesadas pueden acceder a una transmisión en vivo de la presentación a través de la sección de Eventos en el sitio web de relaciones con inversores de Y-mAbs en ir.ymabs.com. La grabación de la presentación estará disponible para su reproducción en el sitio durante 30 días después del evento.
Y-mAbs Therapeutics (Nasdaq: YMAB)는 방사면역요법 및 항체 기반 치료 제품에 전문화된 상업 단계의 생명공학 회사로, 오펜하이머 제35회 연례 생명과학 컨퍼런스에 참여할 것이라고 발표했습니다.
회사의 회장 겸 CEO인 Michael Rossi는 2025년 2월 11일 화요일 오후 4시 40분 ET에 예정된 간담회에 참석할 예정입니다. 투자자 및 관심 있는 분들은 Y-mAbs의 투자자 관계 웹사이트의 이벤트 섹션을 통해 발표의 라이브 웹캐스트에 접속할 수 있습니다(주소: ir.ymabs.com). 발표 녹화는 행사 후 30일 동안 웹사이트에서 재생 가능합니다.
Y-mAbs Therapeutics (Nasdaq: YMAB), une entreprise biopharmaceutique en phase commerciale spécialisée dans la radio-immunothérapie et les produits thérapeutiques basés sur des anticorps pour le traitement du cancer, a annoncé sa participation à la 35ème Conférence Annuelle des Sciences de la Vie d'Oppenheimer.
Le président et PDG de l'entreprise, Michael Rossi, participera à une discussion informelle prévue pour mardi 11 février 2025, à 16h40 HE. Les investisseurs et les intéressés peuvent accéder à un webinaire en direct de la présentation via la section Événements sur le site Web des relations avec les investisseurs de Y-mAbs à l'adresse ir.ymabs.com. L'enregistrement de la présentation restera disponible en replay sur le site pendant 30 jours après l'événement.
Y-mAbs Therapeutics (Nasdaq: YMAB), ein biopharmazeutisches Unternehmen in der kommerziellen Phase, das sich auf Radioimmuntherapie und antikörperbasierte therapeutische Produkte zur Krebsbehandlung spezialisiert hat, hat die Teilnahme an der 35. jährlichen Lebenswissenschaftskonferenz von Oppenheimer angekündigt.
Der Präsident und CEO des Unternehmens, Michael Rossi, wird an einem informellen Gespräch teilnehmen, das für Dienstag, den 11. Februar 2025, um 16:40 Uhr ET angesetzt ist. Investoren und Interessierte können über den Bereich Veranstaltungen auf der Investor-Relations-Website von Y-mAbs unter ir.ymabs.com auf einen Live-Stream der Präsentation zugreifen. Die Aufzeichnung der Präsentation wird für 30 Tage nach der Veranstaltung auf der Website verfügbar sein.
- None.
- None.
NEW YORK, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced that Michael Rossi, President and Chief Executive Officer, will participate in a fireside chat at the Oppenheimer 35th Annual Life Sciences Conference on Tuesday, February 11, 2025 at 4:40 p.m. ET.
A live webcast will be available under the Events section of the Company’s investor relations website at ir.ymabs.com. The webcast will be archived and available for replay for 30 days after the event.
About Y-mAbs
Y-mAbs is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, radioimmunotherapy and antibody-based therapeutic cancer products. The Company’s technologies include its investigational Self-Assembly DisAssembly (“SADA”) Pretargeted Radioimmunotherapy Platform (“PRIT”) and bispecific antibodies generated using the Y-BiClone platform. The Company’s broad and advanced product pipeline includes the anti-GD2 therapy DANYELZA® (naxitamab-gqgk), the first FDA-approved treatment for patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow after a partial response, minor response, or stable disease to prior therapy.
Forward-Looking Statements
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, statements about our business model, including financial outlook for 2024 and beyond.Words such as ‘‘anticipate,’’ ‘‘believe,’’ “contemplate,” ‘‘continue,’’ ‘‘could,’’ ‘‘estimate,’’ ‘‘expect,’’ “hope,” ‘‘intend,’’ ‘‘may,’’ ‘‘might,’’ ‘‘plan,’’ ‘‘potential,’’ ‘‘predict,’’ ‘‘project,’’ ‘‘should,’’ ‘‘target,’’ “will,” ‘‘would’,’ “guidance,” “goal,” “objective,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The Company’s business is subject to risks and uncertainties affecting the Company including those described in the “Risk Factors” section included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, and the Company’s Quarterly Report on Form 10-Q for the quarterly periods ended March 31, 2024, and September 30, 2024, and future filings and reports by the Company. Any forward-looking statements contained in this press release speak only as of the date hereof, and the Company undertakes no obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
SADA®, SADA PRIT™, DANYELZA® and Y-mAbs® are registered trademarks of Y-mAbs Therapeutics, Inc.
Investor Contact:
Courtney Dugan
VP, Head of Investor Relations
cdu@ymabs.com
FAQ
When is Y-mAbs (YMAB) presenting at the Oppenheimer Life Sciences Conference 2025?
How can investors watch Y-mAbs' (YMAB) Oppenheimer Conference presentation?
How long will Y-mAbs' (YMAB) Oppenheimer Conference presentation be available for replay?
What type of presentation will Y-mAbs (YMAB) deliver at the Oppenheimer Conference?
What is Y-mAbs' (YMAB) primary business focus according to the announcement?
